2027 Outlook for Biopharma & CDMO M&A

As we look toward 2027, the dealmaking environment across biopharma, contract development and manufacturing organizations (CDMOs), and pharmaceutical services is settling into a new phase. We’ve finally put behind us both the post-pandemic valuation peaks and the difficult credit markets that stalled middle-market deals. What’s left is a market driven by operational realities: Big Pharma’s need to replace expiring blockbuster revenues, and Biopharma’s reliance on specialized outsourcing partners to bring products to market without using up balance sheet cash.

If you’re CEO/CFO, managing corporate development, or deploying capital at a private equity sponsor, 2027 is shaping up to be a high-stakes year. Deal volume is accelerating, but the gameplan has fundamentally changed. The days of buying a generalist manufacturing company or betting on unproven biotech platforms at inflated multiples are over. Today, success in healthcare M&A requires deep technical specialization, smart cross-border positioning, and portfolio discipline.

The Biopharma Engine: Patent Cliffs & The end of the Megadeals

The single biggest force driving biopharma M&A over the next several years is the looming loss-of-exclusivity (LOE) cliff. With an estimated $300 billion-plus in annual branded drug revenue facing patent expirations through the end of the decade, large-cap pharmaceutical leaders simply cannot afford to sit on the sidelines. They need revenue replacement, and they need it fast.

However, we aren't seeing a return to massive, disruptive mega-mergers that take two years to integrate and destroy culture along the way. Instead, strategic buyers are targeting bolt-on acquisitions in the $1B to $5B range, zeroing in on safer, late-stage clinical assets that can immediately plug gaps in their commercial pipelines.

Where Capital Is Flowing

• Next-Gen Modalities: Deal activity is heavily concentrated around high-demand therapeutic areas. Antibody-drug conjugates (ADCs), RNA therapies, metabolic/GLP-1 combination drugs, and targeted immunology platforms are commanding the highest interest and valuation premiums.
• Cross-Border Asset Sourcing: Western pharma giants are actively scouting biopharma hubs across Europe and Asia-Pacific. We’re seeing a surge in regional buyouts and co-development licensing deals designed to capture clinical-stage innovation before it hits open bidding wars in North America.
• Unlocking Private Equity Liquidity: As public IPO markets remain selective, private equity sponsors holding matured biotech platforms are finding trade sales to strategic pharma acquirers to be their cleanest, highest yield exit strategy.

The CDMO Evolution: Specialized Capabilities Over Large Footprint

The contract development and manufacturing sector is undergoing a massive structural cleanup. The era of the generalist CDMO—trying to be all things to all drug developers—is officially dead. In 2027, buyers and sponsors are rewarding deep, specialized technical capabilities over facility square footage.

Key Shifts in Outsourcing

• Complex Modality Squeeze: As drug pipelines pivot toward biologics, cell and gene therapies, radiopharmaceuticals, and complex sterile injectables (like fill-finish for GLP-1 obesity drugs), biopharma developers are discovering that standard manufacturing lines just won't cut it. CDMOs with specialized, validated cleanrooms and technical talent hold all the leverage.
• Pharma Network Carve-Outs: Big Pharma’s ongoing focus on core R&D is creating a steady pipeline of asset divestments. Instead of building greenfield plants from scratch, CDMOs and PE sponsors are buying underutilized production facilities directly from pharma giants, turning them into multi-client commercial manufacturing hubs.
• Onshoring & Supply Chain Security: Legislative pressure and geopolitical risks surrounding cross-border supply chains are forcing a realignment. Capital is flowing rapidly into North American and European manufacturing infrastructure to ensure domestic supply security.

PitchBook Snapshot: Projected 2027 Biopharma & Outsourcing Data

To give you a better picture of where capital is expected to move across subsectors, here is a breakdown of projected transaction volumes, aggregate values, and expected median EV/EBITDA valuation multiples based on PitchBook trend models:

Strategic Playbooks: PE vs. Corporate Execution

Private Equity: Precision Buy-and-Build

Private equity sponsors can no longer rely on cheap leverage or multiple expansion to hit targeted returns. Going into 2027, successful funds will be getting back to operational basics:

• Targeted Tuck-Ins: Sponsors are executing selective add-on acquisitions to acquire specific technical capabilities rather than just adding volume.
• Secondary Market Flight to Quality: Scaled, high-margin CDMO platforms with long-term commercial supply contracts will command top-tier valuations in sponsor-to-sponsor secondary buyouts.
   

Corporate Strategy: Build vs. Buy vs. Carve-Out

For CDMO executives and pharma corporate development teams, speed-to-market is the ultimate metric:

• The Carve-Out Advantage: Building a greenfield, GMP-compliant facility can take up to 4 or 5 years. Acquiring existing facilities or established platforms remains the fastest way to capture surging demand.
• Earnout Flexibility: On the biopharma side, bridging valuation gaps for clinical-stage assets requires creative, milestone-driven earnout structures tied directly to trial readouts and regulatory approvals.

Practical Takeaways for Business Leaders

If you’re refining your healthcare deal strategy for 2027, keep these core principles in mind:

• Follow the Modalities: Align your CDMO investments directly with the highest-growth drug pipelines—specifically metabolic/GLP-1s, ADCs, radiopharmaceuticals, and specialized biologics.
• Prioritize Regulatory Resilience Early: Cross-border manufacturing transactions face increased regulatory and national security checks. Build supply chain compliance into day-one due diligence.
• Prepare Corporate Divestitures Cleanly: If you're planning a carve-out, start early. Clean financial separation and clear customer transitions protect valuation and prevent deal fatigue.
• Demand Capacity Utilization: Holding high-tech manufacturing capacity means nothing if assets sit empty. Prioritize targets with locked-in, long-term commercial supply agreements.
  Healthcare dealmaking in 2027 won’t be about big headlines—it will be about operational engineering, clinical focus, and execution.

CDI Global is a leading M&A and corporate advisor for middle market transactions, especially cross-border business combinations. We have partners in selected industry groups and maintain offices in more than 35 countries covering the major economic centers of the world.”

For more information go to: https://www.cdiglobal.com/

Brent Peterson, Partner-CDI Global Healthcare Group